[{"address1": "3530 John Hopkins Court", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "844 696 5235", "website": "https://immunitybio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.", "fullTimeEmployees": 628, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard Gerald Adcock", "age": 54, "title": "President, CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 849450, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Barry J. Simon M.D.", "age": 58, "title": "Chief Corporate Affairs Officer & Director", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Leonard S. Sender M.D.", "title": "Chief Operating Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth S. Gabitzsch", "title": "Senior Vice President of Product Development & Vaccine Programs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Manju  Saxena Ph.D.", "title": "SVP of Product Development & Cell Therapy Program", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.97, "open": 9.37, "dayLow": 8.65, "dayHigh": 10.01, "regularMarketPreviousClose": 8.97, "regularMarketOpen": 9.37, "regularMarketDayLow": 8.65, "regularMarketDayHigh": 10.01, "beta": 0.039, "forwardPE": -17.596153, "volume": 14607163, "regularMarketVolume": 14607163, "averageVolume": 6865551, "averageVolume10days": 20121680, "averageDailyVolume10Day": 20121680, "bid": 9.06, "ask": 9.15, "bidSize": 2900, "askSize": 1800, "marketCap": 6194879488, "fiftyTwoWeekLow": 1.25, "fiftyTwoWeekHigh": 10.53, "priceToSalesTrailing12Months": 9959.613, "fiftyDayAverage": 5.5496, "twoHundredDayAverage": 3.57535, "currency": "USD", "enterpriseValue": 6784928256, "floatShares": 145270414, "sharesOutstanding": 677036032, "sharesShort": 54838405, "sharesShortPriorMonth": 53252209, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.081, "heldPercentInsiders": 0.79254997, "heldPercentInstitutions": 0.087519996, "shortRatio": 12.1, "shortPercentOfFloat": 0.39029998, "bookValue": -0.875, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -583196032, "trailingEps": -1.15, "forwardEps": -0.52, "pegRatio": 7.13, "enterpriseToRevenue": 10908.245, "enterpriseToEbitda": -19.79, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IBRX", "underlyingSymbol": "IBRX", "shortName": "ImmunityBio, Inc.", "longName": "ImmunityBio, Inc.", "firstTradeDateEpochUtc": 1438090200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bd5d6a0c-fc2d-3cb7-b719-a9649d726d6f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.15, "targetHighPrice": 9.0, "targetLowPrice": 6.0, "targetMeanPrice": 7.5, "targetMedianPrice": 7.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 266462000, "totalCashPerShare": 0.395, "ebitda": -342851008, "totalDebt": 883676992, "quickRatio": 4.626, "currentRatio": 5.046, "totalRevenue": 622000, "revenuePerShare": 0.001, "returnOnAssets": -0.52111, "freeCashflow": -234658624, "operatingCashflow": -366756992, "revenueGrowth": 0.904, "grossMargins": 1.0, "operatingMargins": -607.92804, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]